The Role of Sentinel Node Biopsy in Skin Cancer: Multimedia

References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. Mar-Apr 2008;58(2):71-96. [Medline].

2. LeJeune FJ, Das Gupta TK, Chaudhuri PK, eds. Malignant Melanoma, Medical and Surgical Management. New York: McGraw-Hill; 1994.

3. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Kim DK, Das Gupta TK. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases. Surgery. Oct 1995;118(4):669-73; discussion 673-5. [Medline].

4. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer. Jan 15 1999;85(2):375-82. [Medline].

5. Voit C, Kron M, Rademaker J, et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol. Feb 20 2005;23(6):1218-27. [Medline].

6. Boone B, Blokx W, De Bacquer D, Lambert J, Ruiter D, Brochez L. The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch. Sep 2008;453(3):257-65. [Medline].

7. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. Jul 2000;7(6):469-74. [Medline].

8. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. Apr 2000;87(4):484-9. [Medline].

9. [Best Evidence] Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. Sep 28 2006;355(13):1307-17. [Medline].

10. Scolyer RA, Murali R, Satzger I, Thompson JF. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol. Sep 2008;17(3):165-74. [Medline].

11. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. May-Jun 2004;54(3):131-49; quiz 182-4. [Medline].

12. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. Mar 14 1998;351(9105):793-6. [Medline].

13. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. Mar 2000;7(2):87-97. [Medline].

14. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. Apr 1992;127(4):392-9. [Medline].

15. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol. 1993;2(3):137-43. [Medline].

16. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. Feb 1996;223(2):217-24. [Medline].

17. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. Oct 1999;230(4):453-63; discussion 463-5. [Medline].

18. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. Jun 2003;10(5):558-61. [Medline].

19. Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ 3rd. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. Jul 2006;13(7):927-32. [Medline].

20. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. Mar 2006;13(3):302-9. [Medline].

21. Corsetti RL, Allen HM, Wanebo HJ. Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol. Jul 2000;7(6):456-60. [Medline].

22. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. Apr 2006;13(4):533-41. [Medline].

23. Gimotty PA, Botbyl J, Soong SJ, Guerry D. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. Nov 1 2005;23(31):8065-75. [Medline].

24. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered?. Cancer Control. Oct 2005;12(4):230-5. [Medline].

25. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. Sep 2008;143(9):892-9; discussion 899-900. [Medline].

26. Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?. Ann Surg. Nov 2003;238(5):743-7. [Medline].

27. Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer. Jan 15 2003;97(2):499-507. [Medline].

28. Urso C, Borgognoni L, Saieva C, et al. Sentinel lymph node biopsy in patients with "atypical Spitz tumors." A report on 12 cases. Hum Pathol. Jul 2006;37(7):816-23. [Medline].

29. Murali R, Sharma RN, Thompson JF, et al. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). Ann Surg Oncol. Jan 2008;15(1):302-9. [Medline].

30. Mehrany K, Otley CC, Weenig RH, Phillips PK, Roenigk RK, Nguyen TH. A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg. Feb 2002;28(2):113-7; discussion 117. [Medline].

31. Mondi MM, Cuenca RE, Ollila DW, Stewart JH 4th, Levine EA. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol. Jan 2007;14(1):218-21. [Medline].

32. Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. May-Jun 2008;14(3):250-4. [Medline].

33. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. Jul 1 2004;86(4):212-23. [Medline].

34. Gomez-Rivera F, Santillan A, McMurphey AB, et al. Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study. Head Neck. Oct 2008;30(10):1284-94. [Medline].

35. Cormier JN, Xing Y, Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. Sep 1 2005;23(25):6054-62. [Medline].

36. Grange F, Vitry F, Granel-Brocard F, et al. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol. May 2008;144(5):629-36. [Medline].

37. Erickson Foster J, Velasco JM, Hieken TJ. Adverse outcomes associated with noncompliance with melanoma treatment guidelines. Ann Surg Oncol. Sep 2008;15(9):2395-402. [Medline].

38. Erickson JL, Velasco JM, Hieken TJ. Compliance with melanoma treatment guidelines in a community teaching hospital: time trends and other variables. Ann Surg Oncol. Apr 2008;15(4):1211-7. [Medline].

39. Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. Jul 15 2000;89(2):236-41. [Medline].

40. Carling T, Pan D, Ariyan S, Narayan D, Truini C. Diagnosis and treatment of interval sentinel lymph nodes in patients with cutaneous melanoma. Plast Reconstr Surg. Mar 2007;119(3):907-13. [Medline].

41. Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. Aug 1999;189(2):195-204. [Medline].

42. Scarsbrook AF, Ganeshan A, Bradley KM. Pearls and pitfalls of radionuclide imaging of the lymphatic system. Part 1: sentinel node lymphoscintigraphy in malignant melanoma. Br J Radiol. Feb 2007;80(950):132-9. [Medline].

43. Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg. Oct 2003;238(4):538-49; discussion 549-50. [Medline].

44. Creager AJ, Shiver SA, Shen P, Geisinger KR, Levine EA. Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Cancer. Jun 1 2002;94(11):3016-22. [Medline].

45. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. Oct 28 1998;280(16):1410-5. [Medline].

46. Romanini A, Manca G, Pellegrino D, et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol. Nov 2005;16(11):1832-40. [Medline].

47. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. Jun 20 2006;24(18):2849-57. [Medline].

48. Frankel TL, Griffith KA, Lowe L, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?. Ann Surg Oncol. Sep 2008;15(9):2403-11. [Medline].

49. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. Sep 10 2008;26(26):4296-303. [Medline].

50. Guggenheim M, Dummer R, Jung FJ, et al. The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma--a retrospective analysis of 392 cases. Br J Cancer. Jun 17 2008;98(12):1922-8. [Medline].

51. Roka F, Mastan P, Binder M, et al. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol. Jan 2008;34(1):82-8. [Medline].

52. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. Jun 2008;15(6):1566-76. [Medline].

53. Scheri RP, Essner R, Turner RR, Ye X, Morton DL. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol. Oct 2007;14(10):2861-6. [Medline].

54. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. Aug 1995;5(4):255-60. [Medline].

55. Reintgen DS, Brobeil A. Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Hematol Oncol Clin North Am. Aug 1998;12(4):807-21, vii. [Medline].

56. Warso MA, Das Gupta TK. Melanoma recurrence in a previously dissected lymph node basin. Arch Surg. Mar 1994;129(3):252-5. [Medline].

57. Chao C, Wong SL, Ross MI, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg. Dec 2002;184(6):520-4; discussion 525. [Medline].

58. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience. Melanoma Res. Feb 2003;13(1):35-43. [Medline].

59. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. Jun 2005;12(6):429-39. [Medline].

60. Caraco C, Marone U, Celentano E, Botti G, Mozzillo N. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Ann Surg Oncol. Sep 2007;14(9):2662-7. [Medline].

61. Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. Sep 2008;248(3):378-86. [Medline].

62. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. Sep 2005;242(3):302-11; discussion 311-3. [Medline].

63. Karim RZ, Scolyer RA, Li W, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. Jun 2008;247(6):1003-10. [Medline].

64. Chan AD, Essner R, Wanek LA, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg. Jul 2000;191(1):16-22; discussion 22-3. [Medline].

65. Koh HK, Sober AJ, Day CL Jr, et al. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol. Aug 1986;4(8):1238-44. [Medline].

66. Kirkwood JM. Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. Dec 1 2005;23(34):8559-63. [Medline].

67. Eggermont AM, Suciu S, Santinami M, et al. EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma: final results of a randomized phase III trial. J Clin Oncol. 2007;25(18 suppl):8504.

68. Testori A, Lazzaro G, Baldini F, et al. The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Res. Jun 2005;15(3):191-8. [Medline].

69. Stretch JR, Somorjai R, Bourne R, et al. Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. Ann Surg Oncol. Nov 2005;12(11):943-9. [Medline].

70. Gadd MA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. Apr 1999;134(4):381-7. [Medline].

71. Gannon CJ, Rousseau DL Jr, Ross MI, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. Dec 1 2006;107(11):2647-52. [Medline].

72. Hochwald SN, Coit DG. Role of elective lymph node dissection in melanoma. Semin Surg Oncol. Jun 1998;14(4):276-82. [Medline].

73. Shen P, Guenther JM, Wanek LA, Morton DL. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?. Ann Surg Oncol. Mar 2000;7(2):114-9. [Medline].

Further Reading

Keywords

sentinel node biopsy, sentinel lymphadenectomy, skin cancer biopsy, selective lymphadenectomy, melanoma surgery, skin cancer, melanoma,  skin cancer surgery, malignant melanoma, lymph node metastasis, sentinel lymph node biopsy, melanoma staging, melanoma treatment, melanoma prognosis

Contributor Information and Disclosures

Author

Tina J Hieken, MD, FACS, Associate Professor, Department of Surgery, Rush University Medical Center; Consulting Physician, Rush North Shore Medical Center and Rush University Medical Center
Tina J Hieken, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Medical Women's Association, American Society of Clinical Oncology, Association for Academic Surgery, Association of Women Surgeons, Central Surgical Association, Chicago Medical Society, Connective Tissue Oncology Society, Illinois State Medical Society, Massachusetts Medical Society, Society for Melanoma Research, and Society of Surgical Oncology
Disclosure: Nothing to disclose.

Medical Editor

Susan M Swetter, MD, Director, Pigmented Lesion and Cutaneous Melanoma Clinic, Associate Professor, Department of Dermatology, Stanford University Medical Center, Veterans Affairs Palo Alto Health Care System
Susan M Swetter, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Pacific Dermatologic Association, Society for Investigative Dermatology, Society for Melanoma Research, and Women's Dermatologic Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

John G Albertini, MD, Consulting Staff, Dermatologic Surgery, The Skin Surgery Center
John G Albertini, MD is a member of the following medical societies: American Academy of Dermatology and American College of Mohs Micrographic Surgery and Cutaneous Oncology
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.